SCHEMBL455315

SCHEMBL455315

COc1ccc(NC(=S)NN=C2Nc3ccc(F)cc3C2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.52
MAOA P21397 3/20 0.50
MAOB P27338 3/20 0.50
MAPT P10636 8/20 0.44
ALDH1A1 P00352 5/20 0.44
TDP1 Q9NUW8 3/20 0.44
KDM4E B2RXH2 3/20 0.44
ATM Q13315 1/20 0.43
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
ALOX12 P18054 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 1/20 0.40
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL454941 0.90 ALDH1A1 (0.46) KDRMAOBMAPTALDH1A1MEN1
SCHEMBL457948 0.87 CES1 (0.47) KDRMAOAMAOBMAPTALDH1A1
SCHEMBL469808 0.85 KDR (0.66) KDRMAOAMAOBMAPTALDH1A1
SCHEMBL456608 0.85 CYP1A2 (0.49) MAOAMAOBMAPTALDH1A1TDP1
SCHEMBL457611 0.84 ALDH1A1 (0.47) MAPTALDH1A1TDP1KDM4EHTT
SCHEMBL457072 0.82 MAPT (0.47) KDRMAPTALDH1A1HTTMEN1
SCHEMBL2877863 0.79 ALDH1A1 (0.46) MAPTALDH1A1HTTMEN1LMNA
SCHEMBL457328 0.79 CES1 (0.50) MAPTALDH1A1TDP1KDM4EMEN1
SCHEMBL470016 0.76 KDR (0.53) KDRMAPTALDH1A1TDP1KDM4E
SCHEMBL13008097 0.74 KDR (0.54) KDRMAPTALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed